tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Enlivex Lists RAIN Treasury Token on WhiteBIT to Boost Liquidity

Story Highlights
  • Enlivex is a clinical-stage immunotherapy company focused on Allocetra for osteoarthritis and uniquely uses RAIN as its primary digital treasury reserve asset.
  • On January 26, 2026, Enlivex reported the January 21 listing of its RAIN token on major European crypto exchange WhiteBIT to expand market access and liquidity.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Enlivex Lists RAIN Treasury Token on WhiteBIT to Boost Liquidity

Claim 50% Off TipRanks Premium

Enlivex ( (ENLV) ) has provided an update.

On January 26, 2026, Enlivex announced that its primary digital treasury asset, the RAIN token, was listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026, giving the token access to a major European and global trading venue. The move is intended to broaden market access and secondary liquidity for RAIN and strengthen the infrastructure around Enlivex’s digital asset treasury strategy, potentially enhancing visibility among crypto market participants while the company continues to advance its core immunotherapy pipeline targeting osteoarthritis.

The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Spark’s Take on ENLV Stock

According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by low leverage on the balance sheet. Technicals are mixed with a short-term bounce but a broader downtrend, and valuation is not supportive given negative earnings and no dividend yield.

To see Spark’s full report on ENLV stock, click here.

More about Enlivex

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in macrophage reprogramming immunotherapies, currently focused on late-stage clinical development of Allocetra™, a novel treatment candidate for osteoarthritis, a highly prevalent and disabling joint disease with significant unmet medical need and no approved disease-modifying drugs. The company is also the first publicly listed firm to adopt a treasury strategy centered on the RAIN token, positioning this digital asset as its primary treasury reserve to give investors exposure to RAIN and promote its role as digital capital.

Average Trading Volume: 4,043,419

Technical Sentiment Signal: Sell

Current Market Cap: $256.4M

Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1